ACREAL has raised 8 billion KRW in pre-Series A funding to advance its AI-driven dental technology, positioning itself for rapid global expansion.

Information on the Target

ACREAL, an AI healthcare company, has successfully secured a total of 8 billion KRW in pre-Series A funding from prominent investors including DSC Investment, SDB Investment, Schmidt, and Suin Investment Capital. This investment has raised their cumulative funding to 14.1 billion KRW, highlighting their strong independent technological capabilities and significant potential for global expansion. The company has developed its own intraoral scanner, branded as 'arcscan', which meets the high-performance standards of premium products in the dental industry and offers competitive pricing.

Intraoral scanners are crucial in the dental AI era as they enable the precise capture of 3D oral data necessary for various dental AI services such as diagnosis, CAD design, treatment planning, and prosthetic production. As the market increasingly demands sophisticated technology, ACREAL's products are positioned to lead the competition in dental AI platforms.

Industry Overview in Korea

The healthcare technology sector in South Korea is rapidly evolving, particularly in the fields of digital health and AI-driven healthcare solutions. With recent government initiatives promoting innovation, companies focusing on AI